GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BridgeBio Pharma Inc (NAS:BBIO) » Definitions » Market Cap

BridgeBio Pharma (BridgeBio Pharma) Market Cap

: $4,651.89 Mil (As of Today)
View and export this data going back to 2019. Start your Free Trial

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). BridgeBio Pharma's share price for the quarter that ended in Dec. 2023 was $40.37. BridgeBio Pharma's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 175.08 Mil. Therefore, BridgeBio Pharma's market cap for the quarter that ended in Dec. 2023 was $7,068.10 Mil.

BridgeBio Pharma's quarterly market cap increased from Jun. 2023 ($2,776.42 Mil) to Sep. 2023 ($4,591.86 Mil) and increased from Sep. 2023 ($4,591.86 Mil) to Dec. 2023 ($7,068.10 Mil).

BridgeBio Pharma's annual market cap declined from Dec. 2021 ($2,457.68 Mil) to Dec. 2022 ($1,147.77 Mil) but then increased from Dec. 2022 ($1,147.77 Mil) to Dec. 2023 ($7,068.10 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. BridgeBio Pharma's Enterprise Value for Today is $5,912.57 Mil.


BridgeBio Pharma Market Cap Historical Data

The historical data trend for BridgeBio Pharma's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BridgeBio Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Market Cap
Premium Member Only Premium Member Only 4,334.21 8,735.79 2,457.68 1,147.77 7,068.10

BridgeBio Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Market Cap Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,147.77 2,660.01 2,776.42 4,591.86 7,068.10

Competitive Comparison

For the Biotechnology subindustry, BridgeBio Pharma's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BridgeBio Pharma Market Cap Distribution

For the Biotechnology industry and Healthcare sector, BridgeBio Pharma's Market Cap distribution charts can be found below:

* The bar in red indicates where BridgeBio Pharma's Market Cap falls into.



BridgeBio Pharma Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

BridgeBio Pharma's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )=Share Price (A: Dec. 2023 )*Shares Outstanding (EOP) (A: Dec. 2023 )
=$40.37*175.083
=$7,068.10

BridgeBio Pharma's Market Cap for the quarter that ended in Dec. 2023 is calculated as

Market Cap (Q: Dec. 2023 )=Share Price (Q: Dec. 2023 )*Shares Outstanding (EOP) (Q: Dec. 2023 )
=$40.37*175.083
=$7,068.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BridgeBio Pharma  (NAS:BBIO) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


BridgeBio Pharma Market Cap Related Terms

Thank you for viewing the detailed overview of BridgeBio Pharma's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


BridgeBio Pharma (BridgeBio Pharma) Business Description

Traded in Other Exchanges
Address
3160 Porter Drive, Suite 250, Palo Alto, CA, USA, 94304
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy. The company focus on genetic diseases because they exist at the intersection of high unmet patient need and tractable biology.
Executives
Hannah Valantine director 1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Frank Mccormick officer: Chairman of Oncology C/O UCSF, 1450 3RD STREET, RM HD-371, SAN FRANCISCO CA 941439001
Randal W Scott director 171 MAIN STREET #225, LOS ALTOS CA 94022
Neil Kumar director, officer: See Remarks C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR, STE 250, PALO ALTO CA 94304
Brian C Stephenson officer: See Remarks 3160 PORTER DR, STE 250, PALO ALTO CA 94304
Viking Global Opportunities Parent Gp Llc 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Investors Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Douglas A. Dachille director 175 WATER STREET, NEW YORK NY 10038
Andrew Lo director C/O ALPHASIMPLEX GROUP, LLC, ONE CAMBRIDGE CENTER, 9TH FLOOR, CAMBRIDGE MA 02142
Ronald J Daniels director C/O MOORE CORPORATION LIMITED, ONE CANTERBURY GREEN, STAMFORD CT 06901
Fred Hassan director C/O CARET GROUP,, 1100 HOLLAND DR., BOCA RATON FL 33487
James C Momtazee director 2884 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
Brent L Saunders director 2000 GALLOPING HILL ROAD, C/O SCHERING PLOUGH CORP, KENILWORTH NJ 07033
Andrea Ellis director C/O BRIDGEBIO PHARMA, INC., 421 KIPLING STREET, PALO ALTO CA 94301
Richard H Scheller director, officer: See Remarks C/O GENENTECH INC, 1 DNA WAY MS 49, SOUTH SAN FRANCISCO CA 94080-4990

BridgeBio Pharma (BridgeBio Pharma) Headlines

From GuruFocus